JP2014529584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014529584A5 JP2014529584A5 JP2014524097A JP2014524097A JP2014529584A5 JP 2014529584 A5 JP2014529584 A5 JP 2014529584A5 JP 2014524097 A JP2014524097 A JP 2014524097A JP 2014524097 A JP2014524097 A JP 2014524097A JP 2014529584 A5 JP2014529584 A5 JP 2014529584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- administered
- pharmaceutically acceptable
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 206010059594 Secondary hypogonadism Diseases 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 201000005670 Anovulation Diseases 0.000 claims description 2
- 206010002659 Anovulatory cycle Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010064919 Hypospermia Diseases 0.000 claims description 2
- 231100000552 anovulation Toxicity 0.000 claims description 2
- 206010003883 azoospermia Diseases 0.000 claims description 2
- 230000037182 bone density Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 230000002513 anti-ovulatory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515278P | 2011-08-04 | 2011-08-04 | |
| US61/515,278 | 2011-08-04 | ||
| PCT/US2012/049451 WO2013020017A1 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186696A Division JP2019023210A (ja) | 2011-08-04 | 2018-10-01 | トランス−クロミフェン代謝物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014529584A JP2014529584A (ja) | 2014-11-13 |
| JP2014529584A5 true JP2014529584A5 (enExample) | 2015-07-02 |
| JP6433785B2 JP6433785B2 (ja) | 2018-12-05 |
Family
ID=46724628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524097A Expired - Fee Related JP6433785B2 (ja) | 2011-08-04 | 2012-08-03 | トランス−クロミフェン代謝物およびその使用 |
| JP2018186696A Pending JP2019023210A (ja) | 2011-08-04 | 2018-10-01 | トランス−クロミフェン代謝物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186696A Pending JP2019023210A (ja) | 2011-08-04 | 2018-10-01 | トランス−クロミフェン代謝物およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9981906B2 (enExample) |
| EP (2) | EP2744777A1 (enExample) |
| JP (2) | JP6433785B2 (enExample) |
| KR (1) | KR20140054110A (enExample) |
| CN (1) | CN103702975B (enExample) |
| AU (2) | AU2012289964B2 (enExample) |
| BR (1) | BR112014000908A2 (enExample) |
| CA (1) | CA2841572C (enExample) |
| CL (1) | CL2014000268A1 (enExample) |
| CO (1) | CO6862154A2 (enExample) |
| CR (1) | CR20140124A (enExample) |
| EA (1) | EA201490416A1 (enExample) |
| IL (1) | IL230287B (enExample) |
| MX (1) | MX355316B (enExample) |
| MY (2) | MY170718A (enExample) |
| NI (1) | NI201400008A (enExample) |
| PH (1) | PH12014500144A1 (enExample) |
| SG (1) | SG10201606425WA (enExample) |
| UA (1) | UA113291C2 (enExample) |
| WO (1) | WO2013020017A1 (enExample) |
| ZA (1) | ZA201400406B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120284764A1 (en) * | 2011-05-05 | 2012-11-08 | Keith Ball | Method and system for requesting services by a media device |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| CA2872644A1 (en) | 2012-05-31 | 2013-12-05 | Allergan Pharmaceuticals International Limited | Formulations and methods for vaginal delivery of antiprogestins |
| CN104994877A (zh) | 2012-11-02 | 2015-10-21 | 利普生物药剂公司 | 用于癌症治疗的反式-克罗米芬 |
| US9545411B2 (en) | 2012-11-02 | 2017-01-17 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| US20190008804A1 (en) * | 2016-01-12 | 2019-01-10 | Repros Therapeutics Inc. | Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions |
| JP2019506425A (ja) * | 2016-02-25 | 2019-03-07 | アスペン パーク ファーマシューティカルズ，インコーポレイティド | クロミフェン異性体の経口剤形および続発性性腺機能低下症を治療するために経口剤形を使用する方法 |
| CN108463453A (zh) | 2016-04-22 | 2018-08-28 | 意大利合成制造有限公司 | 用于制备具有针状晶体习性的柠檬酸恩氯米芬的方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2914563A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Therapeutic composition |
| IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
| US4061733A (en) | 1976-10-15 | 1977-12-06 | Narayan Vishwanath Gunjikar | Veterinary compositions for inducing estrus in animals and method |
| US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| EP0206021B1 (de) | 1985-06-08 | 1988-08-10 | ASTA Pharma AG | Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans |
| US4820736A (en) * | 1987-03-20 | 1989-04-11 | Yale University | Use of clomiphene to predict fertility in a human female |
| GB8926171D0 (en) | 1989-11-20 | 1990-01-10 | Applied Research Systems | Treatment of infertility |
| JPH04312522A (ja) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | 徐放性錠剤の製造方法 |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| AU672234B2 (en) * | 1992-09-15 | 1996-09-26 | Merrell Dow Pharmaceuticals Inc. | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors |
| US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| WO1995035093A1 (en) | 1994-06-17 | 1995-12-28 | University Of Nebraska Board Of Regents | In situ gel-forming delivery vehicle for bio-affecting substances, and method of use |
| DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| CA2228610C (en) | 1995-08-17 | 2008-06-03 | Heidi Rolfes | Controlled release products |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| IL120262A (en) | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
| ATE277739T1 (de) | 1996-10-28 | 2004-10-15 | Gen Mills Inc | Einbettung und einkapselung von teilchen zur kontrollierten abgabe |
| JP4496316B2 (ja) | 1997-04-03 | 2010-07-07 | エーザイ インコーポレイテッド | 生分解性テレフタレートポリエステル−ポリホスフェートポリマー、組成物、物品、並びにその製造及び使用方法 |
| US6653297B1 (en) | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| US6342250B1 (en) | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
| US20040186185A1 (en) | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| NZ510201A (en) | 1998-07-30 | 2002-10-25 | Stoller Ets | Treatment of plants with salicylic acid and organic amines |
| DE69935335T2 (de) | 1998-08-07 | 2007-11-22 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazole als modulatoren des östrogenrezeptors |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP5184727B2 (ja) | 1999-06-11 | 2013-04-17 | ワトソン ファーマシューティカルズ， インコーポレイテッド | 女性への非経口アンドロゲンステロイドの投与 |
| CA2321321A1 (en) | 1999-09-30 | 2001-03-30 | Isotis B.V. | Polymers loaded with bioactive agents |
| US6258802B1 (en) | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
| US20020004065A1 (en) | 2000-01-20 | 2002-01-10 | David Kanios | Compositions and methods to effect the release profile in the transdermal administration of active agents |
| EP1251855A1 (en) | 2000-01-28 | 2002-10-30 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
| US7067557B2 (en) | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| WO2001091744A1 (en) | 2000-05-26 | 2001-12-06 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| AU2002213198A1 (en) | 2000-10-11 | 2002-04-22 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| US6743448B2 (en) | 2000-12-11 | 2004-06-01 | Abraham H. Kryger | Topical testosterone formulations and associated methods |
| CN1289075C (zh) | 2001-07-09 | 2006-12-13 | 佐纳根有限公司 | 富含反式克罗米酚的克罗米酚组合物的用途 |
| US7173064B2 (en) | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| EP1429779A2 (en) | 2001-09-21 | 2004-06-23 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| US20060269611A1 (en) | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US7105679B2 (en) | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| EP1776098A1 (en) | 2004-07-14 | 2007-04-25 | Repros Therapeutics Inc. | Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol |
| US20060293294A1 (en) | 2004-09-03 | 2006-12-28 | Hormos Medical Corporation | Method for treatment or prevention of androgen deficiency |
| CN101115709B (zh) * | 2004-12-13 | 2011-04-13 | 小野药品工业株式会社 | 氨基羧酸衍生物及其医药用途 |
| WO2006084153A2 (en) * | 2005-02-04 | 2006-08-10 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
| EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| NZ560551A (en) | 2005-03-22 | 2010-02-26 | Repros Therapeutics Inc | Dosing regimes for trans-clomiphene |
| EP1896134A2 (en) | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| US20080306035A1 (en) * | 2005-08-05 | 2008-12-11 | Repros Therapeutics Inc. | Methods and Compositions for Treating Female Infertility Using Clomiphene |
| US7613937B2 (en) | 2005-10-31 | 2009-11-03 | Hewlett-Packard Development Company, L.P. | Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer |
| WO2007095716A1 (en) | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
| EP1829534A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
| WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| ATE542327T1 (de) | 2007-06-26 | 2012-02-15 | Media Patents Sl | Vorrichtung zur verwaltung von mehrfachsendungsgruppen |
| US8106037B2 (en) | 2007-08-03 | 2012-01-31 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
| MX2010004195A (es) * | 2007-10-16 | 2010-06-02 | Repros Therapeutics Inc | Trans-clomifeno para el sindrome metabolico. |
| US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
| TWI458478B (zh) | 2008-11-07 | 2014-11-01 | Repros Therapeutics Inc | 用於代謝症候群與第２型糖尿病的反式氯米芬 |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| WO2013020215A1 (en) | 2011-08-09 | 2013-02-14 | Adams Kenneth W | Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
| MX2014009322A (es) | 2012-02-29 | 2014-11-10 | Repros Therapeutics Inc | Terapia de combinacion para el tratamiento de la deficiencia androgenica. |
| SG10201704820SA (en) | 2012-08-21 | 2017-07-28 | Repros Therapeutics Inc | Trans-clomiphene formulations and uses thereof |
| CN103351304B (zh) | 2013-07-01 | 2015-12-09 | 暨明医药科技（苏州）有限公司 | 一种克罗米芬的合成方法 |
-
2012
- 2012-03-08 UA UAA201402168A patent/UA113291C2/uk unknown
- 2012-08-03 PH PH1/2014/500144A patent/PH12014500144A1/en unknown
- 2012-08-03 MX MX2014000825A patent/MX355316B/es active IP Right Grant
- 2012-08-03 CN CN201280038230.6A patent/CN103702975B/zh not_active Expired - Fee Related
- 2012-08-03 AU AU2012289964A patent/AU2012289964B2/en not_active Ceased
- 2012-08-03 WO PCT/US2012/049451 patent/WO2013020017A1/en not_active Ceased
- 2012-08-03 EP EP12750508.9A patent/EP2744777A1/en not_active Withdrawn
- 2012-08-03 EA EA201490416A patent/EA201490416A1/ru unknown
- 2012-08-03 CA CA2841572A patent/CA2841572C/en not_active Expired - Fee Related
- 2012-08-03 EP EP18161551.9A patent/EP3351527A1/en not_active Withdrawn
- 2012-08-03 KR KR1020147004588A patent/KR20140054110A/ko not_active Ceased
- 2012-08-03 MY MYPI2014000022A patent/MY170718A/en unknown
- 2012-08-03 SG SG10201606425WA patent/SG10201606425WA/en unknown
- 2012-08-03 JP JP2014524097A patent/JP6433785B2/ja not_active Expired - Fee Related
- 2012-08-03 US US14/236,868 patent/US9981906B2/en not_active Expired - Fee Related
- 2012-08-03 BR BR112014000908A patent/BR112014000908A2/pt active Search and Examination
- 2012-08-03 MY MYPI2017001676A patent/MY191802A/en unknown
-
2014
- 2014-01-02 IL IL230287A patent/IL230287B/en active IP Right Grant
- 2014-01-17 ZA ZA2014/00406A patent/ZA201400406B/en unknown
- 2014-01-24 CO CO14014339A patent/CO6862154A2/es unknown
- 2014-01-30 NI NI201400008A patent/NI201400008A/es unknown
- 2014-02-03 CL CL2014000268A patent/CL2014000268A1/es unknown
- 2014-03-13 CR CR20140124A patent/CR20140124A/es unknown
-
2017
- 2017-06-20 AU AU2017204171A patent/AU2017204171A1/en not_active Abandoned
-
2018
- 2018-10-01 JP JP2018186696A patent/JP2019023210A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6401317B2 (ja) | がんを治療するためのシステム、方法、および製剤 | |
| JP2013501731A5 (enExample) | ||
| TW200410711A (en) | Prevention and treatment of androgen-deprivation induced osteoporosis | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| KR102490547B1 (ko) | 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물 | |
| JP2014511383A5 (enExample) | ||
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| RU2014113334A (ru) | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний | |
| JP2017533972A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| CN107072969B (zh) | 使用顺式氯米芬治疗雄激素剥夺疗法诱导的热潮红和骨丢失 | |
| KR20160067225A (ko) | 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제 | |
| KR20220098082A (ko) | 종양 감소 제형 및 그의 사용 방법 | |
| JP2012525358A5 (enExample) | ||
| RU2017134553A (ru) | Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов, и их применение | |
| JP2015506988A5 (enExample) | ||
| JP2015533150A (ja) | 前立腺がんの根治的又は対症的処置における使用のためのホスフェストロール | |
| Saidi et al. | Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience | |
| WO1995012383A1 (en) | An injectable solution of testosterone undecanoate | |
| JP2015506988A (ja) | 半減期の短い選択的エストロゲン受容体モジュレーターおよびその使用 | |
| RU2014111060A (ru) | Лиганды рецептора эстрогена и способы их применения | |
| JP2014524479A5 (enExample) | ||
| JP2013503908A5 (enExample) | ||
| JP2016509571A (ja) | 雌哺乳動物でのがんの根治的又は対症的処置における使用のためのホスフェストロール | |
| JP2016513647A (ja) | レプチン生産を増進するビマトプロスト |